Asthma phenotyping in primary care : applying the International Severe Asthma Registry eosinophil phenotype algorithm across all asthma severities.

Funding: The OPCRD is established and maintained by Optimum Patient Care (OPC) Ltd. This study was funded by AstraZeneca and conducted collaboratively with the OPRI Pte Ltd and OPC Global Ltd. Acknowledgements We thank James Zangrilli, MD, and the entire ISAR Steering Committee for their valued contribution to the design of the study and interpretation of findingsPeer reviewedPublisher PD